"Something is rotten in the state of Denmark," as Hamlet said in Shakespeare’s time. It was true then, and it’s true today.

While Senate Democrats are holding our government hostage to their ridiculous shutdown so they can provide free healthcare to illegal aliens, federal services are going unfulfilled. One foreign company is trying to exploit this to keep its profits as fat as possible.

Novo Nordisk, a biotech company based in Denmark, is attempting to intervene in the American pharmaceutical market to suppress competition, protect its dominant market position, and stop a weight-loss drug competitor from entering the market.

Novo, the maker of Ozempic and Wegovy, has a significant market share in the GLP1 drug space, which has revolutionized the medical treatment of obesity. Given

See Full Page